Nom du produit:4-(4-Nitrophenyl)piperidine
IUPAC Name:4-(4-nitrophenyl)piperidine
- CAS：26905-03-3
- Formule moléculaire：C11H14N2O2
- Pureté：95%+
- Numéro de catalogue：CM275089
- Poids moléculaire：206.25
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:26905-03-3
- Formule moléculaire:C11H14N2O2
- Point de fusion:-
- Code SMILES:O=[N+](C1=CC=C(C2CCNCC2)C=C1)[O-]
- Densité:
- Numéro de catalogue:CM275089
- Poids moléculaire:206.25
- Point d'ébullition:
- N° Mdl:MFCD06804549
- Stockage:
Category Infos
- Piperidines
- Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.
- Piperidine,Piperidine Price
- if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.
Column Infos
- NX-2127
- Existing BTK inhibitors directly bind to the active site of BTK and face challenges such as acquired resistance or incomplete responses over time. PROTAC-induced BTK degradation works as a novel alternative therapy for drug-resistant cancers. The latest journal Science publishes the identification of BTK mutations that are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Nurix Therapeutics’ TPD compound NX-2127 is a first-in-class, dual-function small-molecule protein degrader. It drives targeted BTK and transcription factor IKAROS (IKZF1/3) degradation through ubiquitination and proteasomal degradation, adding combined benefit. NX-2127 is under development of phase I clinical trials that shows promising results and a manageable safety profile for the treatment of relapsed/ refractory B-cell malignancies.
Recherche 
+86 21 5895 0110 
